Product Description
Shanghai Baoji Pharmaceutical is developing BJ-009 for Oncology patients. (Sourced from: https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shanghai Baoji Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20255246 |
CTR20255246 | N/A |
Unknown |
Respiratory Tract Infections|Urinary Tract Infections|Sepsis|Endocarditis|Reproductive Tract Infections|Soft Tissue Infections |
None |
2026-01-25 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|